克莱曼德医药申请使用MDMA和PEA的组合疗法的专利, 与SciSparc Ltd合作以提高安全性和有效性. Clearmind Medicine applies for a patent for combination therapy using MDMA and PEA, partnering with SciSparc Ltd to enhance safety and efficacy.

Clearmind Medicine 宣布了一项使用 MDMA 和 N-酰基乙醇胺（包括棕榈酰乙醇酰胺 （PEA））的联合疗法的国际专利申请。 Clearmind Medicine has announced an international patent application for a combination therapy using MDMA and N-Acylethanolamines, including Palmitoylethanolamide (PEA). 通过与SciSparc有限公司的合作,旨在提高安全性和治疗效果,解决FDA对MDMA安全性的担忧. This collaboration with SciSparc Ltd. aims to enhance safety and therapeutic efficacy, addressing FDA concerns over MDMA's safety. 这些公司提出了多项专利申请,寻求创新治疗精神疾病和上瘾的办法,同时减少MDMA剂量。 The companies have filed multiple patents, seeking to innovate treatments for mental health disorders and addictions while reducing MDMA dosages.